Literature DB >> 2346390

Seizures in human immunodeficiency virus infection.

M C Wong1, N D Suite, D R Labar.   

Abstract

Among 630 patients with human immunodeficiency virus infection, 70 patients with new-onset seizures were studied. Generalized seizures occurred in 66 patients (94%): they occurred as the initial seizure in 56 patients (80%) and during follow-up in another 10 patients (14%). Partial seizures (18 patients), status epilepticus (10 patients), and recurrent seizures (38 patients) were also noted. Identified processes included cerebral toxoplasmosis in 11 patients, cerebral lymphoma in 8, metabolic derangement in 8, cryptococcal meningitis in 7, and vascular infarction in 4. In 32 patients (46%) seizures were not associated with identifiable brain lesions and were believed to result from human immunodeficiency virus cerebral infection. Phenytoin treatment was associated with adverse drug reactions in 16 of 62 patients who received it. Our results suggest that the majority of patients with human immunodeficiency virus and seizures do not have secondary focal brain lesions as the cause of the seizures and that human immunodeficiency virus infection alone can, and often does, cause seizures.

Entities:  

Mesh:

Year:  1990        PMID: 2346390     DOI: 10.1001/archneur.1990.00530060048015

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  21 in total

1.  Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs.

Authors:  Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 2.  Progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

3.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 4.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

Review 5.  Seizures in HIV-seropositive individuals: epidemiology and treatment.

Authors:  Frank Romanelli; Melody Ryan
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

7.  New-onset seizure in HIV-infected adult Zambians: A search for causes and consequences.

Authors:  Omar K Siddiqi; Melissa A Elafros; Christopher M Bositis; Igor J Koralnik; William H Theodore; Jason F Okulicz; Lisa Kalungwana; Michael J Potchen; Izukanji Sikazwe; Gretchen L Birbeck
Journal:  Neurology       Date:  2016-12-21       Impact factor: 9.910

Review 8.  The pathogenesis of the neurological complications of HIV-1 infection.

Authors:  B J Brew
Journal:  Genitourin Med       Date:  1993-10

Review 9.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.

Authors:  Jason F Okulicz; Greg A Grandits; Jacqueline A French; Emilio Perucca; Jomy M George; Michael L Landrum; Edward P Acosta; Gretchen L Birbeck
Journal:  Epilepsy Res       Date:  2012-07-24       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.